TMCI Key Statistics, Chart & Performance
The current stock price of TMCI is 1.975 USD. In the past month the price decreased by -25.36%. In the past year, price decreased by -79.27%.
TMCI Technical Analysis
TMCI Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to TMCI. TMCI has a bad profitability rating. Also its financial health evaluation is rather negative.
TMCI Financial Highlights
Over the last trailing twelve months TMCI reported a non-GAAP Earnings per Share(EPS) of -0.8. The EPS increased by 14.89% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -25.49% | ||
| ROE | -56.18% | ||
| Debt/Equity | 0.62 |
TMCI Forecast & Estimates
11 analysts have analysed TMCI and the average price target is 4.93 USD. This implies a price increase of 149.84% is expected in the next year compared to the current price of 1.975.
For the next year, analysts expect an EPS growth of 4.7% and a revenue growth 2.04% for TMCI
TMCI Ownership
TMCI Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 19.51 | 195.24B | ||
| ISRG | INTUITIVE SURGICAL INC | 48.19 | 175.531B | ||
| SYK | STRYKER CORP | 23.67 | 138.077B | ||
| BSX | BOSTON SCIENTIFIC CORP | 21.13 | 110.114B | ||
| IDXX | IDEXX LABORATORIES INC | 43.25 | 51.625B | ||
| BDX | BECTON DICKINSON AND CO | 11.43 | 48.913B | ||
| EW | EDWARDS LIFESCIENCES CORP | 26.34 | 44.712B | ||
| RMD | RESMED INC | 20.84 | 38.469B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 15.67 | 36.104B | ||
| DXCM | DEXCOM INC | 26.95 | 26.584B |
Related stock screener links
View all stocks in the Health Care Equipment Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About TMCI
Company Profile
Treace Medical Concepts, Inc. engages in the design, manufacture, and marketing of orthopedic medical devices and biologic solutions. The company is headquartered in Ponte Vedra, Florida and currently employs 477 full-time employees. The company went IPO on 2021-04-23. The company is advancing the standard of care for the surgical management of bunion and related midfoot deformities. The company has patented the Lapiplasty 3D Bunion Correction System a combination of instruments, implants, and surgical methods designed to surgically correct all three planes of the bunion deformity and secure the unstable joint, addressing the root cause of the bunion and helping patients get back to their active lifestyles. The company has Adductoplasty Midfoot Correction System, designed for reproducible surgical correction of midfoot deformities, the SpeedMTP Rapid Compression Implant for addressing bunions through big toe joint fusions, and two systems for minimally invasive osteotomy surgeries: the Nanoplasty 3D Minimally Invasive Bunion Correction System and the Percuplasty Percutaneous 3D Bunion Correction System. The company sells its products to physicians, surgeons, ambulatory surgery centers, hospitals, and stocking distributors.
Company Info
TREACE MEDICAL CONCEPTS INC
100 Palmetto Park Place
Ponte Vedra FLORIDA 32081 US
CEO: John T. Treace
Employees: 477
Phone: 19043735940
TREACE MEDICAL CONCEPTS INC / TMCI FAQ
Can you describe the business of TREACE MEDICAL CONCEPTS INC?
Treace Medical Concepts, Inc. engages in the design, manufacture, and marketing of orthopedic medical devices and biologic solutions. The company is headquartered in Ponte Vedra, Florida and currently employs 477 full-time employees. The company went IPO on 2021-04-23. The company is advancing the standard of care for the surgical management of bunion and related midfoot deformities. The company has patented the Lapiplasty 3D Bunion Correction System a combination of instruments, implants, and surgical methods designed to surgically correct all three planes of the bunion deformity and secure the unstable joint, addressing the root cause of the bunion and helping patients get back to their active lifestyles. The company has Adductoplasty Midfoot Correction System, designed for reproducible surgical correction of midfoot deformities, the SpeedMTP Rapid Compression Implant for addressing bunions through big toe joint fusions, and two systems for minimally invasive osteotomy surgeries: the Nanoplasty 3D Minimally Invasive Bunion Correction System and the Percuplasty Percutaneous 3D Bunion Correction System. The company sells its products to physicians, surgeons, ambulatory surgery centers, hospitals, and stocking distributors.
What is the stock price of TREACE MEDICAL CONCEPTS INC today?
The current stock price of TMCI is 1.975 USD. The price decreased by -5.5% in the last trading session.
What is the dividend status of TREACE MEDICAL CONCEPTS INC?
TMCI does not pay a dividend.
How is the ChartMill rating for TREACE MEDICAL CONCEPTS INC?
TMCI has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Can you provide the market cap for TREACE MEDICAL CONCEPTS INC?
TREACE MEDICAL CONCEPTS INC (TMCI) has a market capitalization of 125.85M USD. This makes TMCI a Micro Cap stock.
What is the ownership structure of TREACE MEDICAL CONCEPTS INC (TMCI)?
You can find the ownership structure of TREACE MEDICAL CONCEPTS INC (TMCI) on the Ownership tab.